The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
The chemical biology of clinically tolerated NMDA receptor antagonists
Abstract
Most neuroprotective drugs have failed in clinical trials because of side‐effects, causing normal brain function to become compromised. A case in point concerns antagonists of the N‐methyl‐D‐aspartate type of glutamate receptor (NMDAR). Glutamate receptors are essential to the normal function of the central nervous system. However, their excessive activation by excitatory amino acids, such as glutamate itself, is thought to contribute to neuronal damage in many neurological disorders ranging from acute hypoxic‐ischemic brain injury to chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. The dual role of NMDARs in particular for normal and abnormal functioning of the nervous system imposes important constraints on possible therapeutic strategies aimed at ameliorating neurological diseases. Blockade of excessive NMDAR activity must therefore be achieved without interference with its normal function. In general, NMDAR antagonists can be categorized pharmacologically according to the site of action on the receptor‐channel complex. These include drugs acting at the agonist (NMDA) or co‐agonist (glycine) sites, channel pore, and modulatory sites, such as the S‐nitrosylation site where nitric oxide (NO) reacts with critical cysteine thiol groups. Because glutamate is thought to be the major excitatory transmitter in the brain, generalized inhibition of a glutamate receptor subtype like the NMDAR causes side‐effects that clearly limit the potential for clinical applications. Both competitive NMDA and glycine antagonists, even although effective in preventing glutamate‐mediated neurotoxicity, will cause generalized inhibition of NMDAR activities and thus have failed in many clinical trials. Open‐channel block with the property of uncompetitive antagonism is the most appealing strategy for therapeutic intervention during excessive NMDAR activation as this action of blockade requires prior activation of the receptor. This property, in theory, leads to a higher degree of channel blockade in the presence of excessive levels of glutamate and little blockade at relatively lower levels, for example, during physiological neurotransmission. Utilizing this molecular strategy of action, we review here the logical process that we applied over the past decade to help develop memantine as the first clinically tolerated yet effective agent against NMDAR‐mediated neurotoxicity. Phase 3 (final) clinical trials have shown that memantine is effective in treating moderate‐to‐severe Alzheimer's disease while being well tolerated. Memantine is also currently in trials for additional neurological disorders, including other forms of dementia, glaucoma, and severe neuropathic pain. Additionally, taking advantage of memantine's preferential binding to open channels and the fact that excessive NMDAR activity can be down‐regulated by S‐nitrosylation, we have recently developed combinatorial drugs called NitroMemantines. These drugs use memantine as a homing signal to target NO to hyperactivated NMDARs in order to avoid systemic side‐effects of NO such as hypotension (low blood pressure). These second‐generation memantine derivatives are designed as pathologically activated therapeutics, and in preliminary studies appear to have even greater neuroprotective properties than memantine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 16×
“These detrimental processes include Ca2+ overload of mitochondria, resulting in oxygen free radical formation, activation of caspases, and release of apoptosisinducing factor; Ca2+-dependent activation of neuronal NOS, leading to increased NO production and the formation of toxic peroxynitrite (ONOO–) and S-nitrosylat…”
BackgroundInfluentialVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
Self-citationLipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P., & Lipton, S. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7162 · Cited by 1,958
Self-citationExcitatory amino acid neurotoxicity and neurodegenerative disease
Meldrum, B., & Garthwaite, J. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90184-a · Cited by 1,771
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Blockade of N -Methyl-D-Aspartate Receptors May Protect Against Ischemic Damage in the Brain
Simon, R. P., Swan, J. H., Griffiths, T., & Meldrum, B. S. (1984) · Science · doi:10.1126/science.6093256 · Cited by 1,682
Mattson, M., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00376.1992 · Cited by 1,627
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
A double‐blind, placebo‐controlled trial
Pinals, R. S., Kaplan, S. B., Lawson, J. G., & Hepburn, B. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291202 · Cited by 1,355
S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding
Hara, M. R., Agrawal, N., Kim, S. F., Cascio, M. B., Fujimuro, M., Ozeki, Y., Takahashi, M., Cheah, J. H., Tankou, S. K., Hester, L. D., et al. (2005) · Nature Cell Biology · doi:10.1038/ncb1268 · Cited by 1,070
The Toxic Effect of Sodium L-Glutamate on the Inner Layers of the Retina
LUCAS, D. R., & NEWHOUSE, J. P. (1957) · Archives of Ophthalmology · doi:10.1001/archopht.1957.00940010205006 · Cited by 1,063
Modulation of Neuronal Migration by NMDA Receptors
Komuro, H., & Rakic, P. (1993) · Science · doi:10.1126/science.8096653 · Cited by 1,041
Xiong, Z.-G., Zhu, X.-M., Chu, X.-P., Minami, M., Hey, J., Wei, W.-L., MacDonald, J. F., Wemmie, J. A., Price, M. P., Welsh, M. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.08.026 · Cited by 1,025
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures
Dawson, V., Dawson, T., Bartley, D., Uhl, G., & Snyder, S. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-06-02651.1993 · Cited by 1,014
Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis.
Quigley, H. A., Nickells, R. W., Kerrigan, L. A., Pease, M. E., Thibault, D., & Zack, D. J. (1995) · PubMed · Cited by 935
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Self-citationParsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
A Key Role for TRPM7 Channels in Anoxic Neuronal Death
Aarts, M., Iihara, K., Wei, W.-L., Xiong, Z.-G., Arundine, M., Cerwinski, W., MacDonald, J. F., & Tymianski, M. (2003) · Cell · doi:10.1016/s0092-8674(03)01017-1 · Cited by 782
Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex
Lei, S. Z., Pan, Z.-H., Aggarwal, S. K., Chen, H.-S. V., Hartman, J., Sucher, N. J., & Lipton, S. A. (1992) · Neuron · doi:10.1016/0896-6273(92)90130-6 · Cited by 743
Self-citationChen, H., Pellegrini, J., Aggarwal, S., Lei, S., Warach, S., Jensen, F., & Lipton, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 629
Self-citationβ-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
Koh, J.-Y., Yang, L. L., & Cotman, C. W. (1990) · Brain Research · doi:10.1016/0006-8993(90)91355-k · Cited by 617
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
N-methyl-D-aspartate receptor antagonist desegregates eye-specific stripes.
Cline, H. T., Debski, E. A., & Constantine-Paton, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.12.4342 · Cited by 527
Mechanism of action of memantine
JOHNSON, J., & KOTERMANSKI, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 502
NMDA receptor pathways as drug targets
Kemp, J. A., & McKernan, R. M. (2002) · Nature Neuroscience · doi:10.1038/nn936 · Cited by 476
Alternatively spliced isoforms of the NMDARI receptor subunit
Zukin, R. S., & Bennett, M. V. L. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93920-s · Cited by 456
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation
Choi, Y.-B., Tenneti, L., Le, D. A., Ortiz, J., Bai, G., Chen, H.-S. V., & Lipton, S. A. (2000) · Nature Neuroscience · doi:10.1038/71090 · Cited by 425
Self-citationDanysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Brain Damage in Infant Mice following Oral Intake of Glutamate, Aspartate or Cysteine
OLNEY, J. W., & HO, O.-L. (1970) · Nature · doi:10.1038/227609b0 · Cited by 384
Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation
Lipton, S. A., Choi, Y.-B., Takahashi, H., Zhang, D., Li, W., Godzik, A., & Bankston, L. A. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02245-2 · Cited by 375
Self-citationOLNEY, J. W. (1969) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196907000-00007 · Cited by 352
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels
Bormann, J. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90385-3 · Cited by 351
N-methyl-D-aspartate receptor antagonists disrupt the formation of a mammalian neural map.
Simon, D. K., Prusky, G. T., O'Leary, D. D., & Constantine-Paton, M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10593 · Cited by 323
Coupling between NMDA Receptor and Acid-Sensing Ion Channel Contributes to Ischemic Neuronal Death
Gao, J., Duan, B., Wang, D.-G., Deng, X.-H., Zhang, G.-Y., Xu, L., & Xu, T.-L. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.011 · Cited by 323
Lees, K. R., Asplund, K., Carolei, A., Davis, S. M., Diener, H.-C., Kaste, M., Orgogozo, J.-M., & Whitehead, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02326-6 · Cited by 309
Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons
Budd, S. L., Tenneti, L., Lishnak, T., & Lipton, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100121097 · Cited by 284
Self-citationSacco, R. L., DeRosa, J. T., Haley, Jr., Levin, B., Ordronneau, P., Phillips, S. J., Rundek, T., Snipes, R. G., Thompson, J. L. P., & for the GAIN Americas Investigators (2001) · JAMA · doi:10.1001/jama.285.13.1719 · Cited by 283
Chen, H. S., & Lipton, S. A. (1997) · The Journal of Physiology · doi:10.1113/jphysiol.1997.sp021909 · Cited by 282
Self-citationChronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine.
Vorwerk, C. K., Lipton, S. A., Zurakowski, D., Hyman, B. T., Sabel, B. A., & Dreyer, E. B. (1996) · PubMed · Cited by 281
Self-citationHarkany, T., Ábrahám, I., Timmerman, W., Laskay, G., Tóth, B., Sasvári, M., Kónya, C., Sebens, J. B., Korf, J., Nyakas, C., et al. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00164.x · Cited by 273
Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)
Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265
Lipton, S. A. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90198-u · Cited by 256
Self-citation(3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
Kornhuber, J., Mack-Burkhardt, F., Riederer, P., Hebenstreit, G. F., Reynolds, G. P., Andrews, H. B., & Beckmann, H. (1989) · Journal of Neural Transmission · doi:10.1007/bf01248936 · Cited by 250
Trapping Channel Block of NMDA-Activated Responses By Amantadine and Memantine
Blanpied, T. A., Boeckman, F. A., Aizenman, E., & Johnson, J. W. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.77.1.309 · Cited by 249
Sites for Antagonism on the N-Methyl-D-Aspartate Receptor Channel Complex
Wong, E. H. F., & Kemp, J. A. (1991) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.31.040191.002153 · Cited by 218
Structure and gating of the glutamate receptor ion channel
WOLLMUTH, L. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.005 · Cited by 217
Chen, H.-S. V., Wang, Y. F., Rayudu, P. V., Edgecomb, P., Neill, J. C., Segal, M. M., Lipton, S. A., & Jensen, F. E. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00163-8 · Cited by 202
Self-citationAracava, Y., Pereira, E. F. R., Maelicke, A., & Albuquerque, E. X. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077172 · Cited by 200
Rammes, G., Rupprecht, R., Ferrari, U., Zieglgänsberger, W., & Parsons, C. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01872-9 · Cited by 200
Nitric oxide mediates N-methyl-d-aspartate receptor-induced activation of p21ras
Yun, H.-Y., Gonzalez-Zulueta, M., Dawson, V. L., & Dawson, T. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5773 · Cited by 190
Emerging treatments for stroke in humans
Koroshetz, W. J., & Moskowitz, M. A. (1996) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(96)10020-1 · Cited by 189
Calcium, free radicals and excitotoxins in neuronal apoptosis
Lipton, S. A., & Nicotera, P. (1998) · Cell Calcium · doi:10.1016/s0143-4160(98)90115-4 · Cited by 188
Self-citationA 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.49 · Cited by 181
Kashiwagi, K., Masuko, T., Nguyen, C. D., Kuno, T., Tanaka, I., Igarashi, K., & Williams, K. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12116-5 · Cited by 166
Pharmacology of cerebral ischemia
Polinsky, R. J. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)90034-9 · Cited by 164
Wollmuth, L. P., Kuner, T., & Sakmann, B. J. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.013bx.x · Cited by 156
Memantine prevents HIV coat protein‐induced neuronal injury in vitro
Lipton, S. A. (1992) · Neurology · doi:10.1212/wnl.42.7.1403 · Cited by 152
Self-citationNeuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Palmer, G. C. (2001) · Current Drug Targets · doi:10.2174/1389450013348335 · Cited by 145
Low Doses of Memantine Disrupt Memory in Adult Rats
Creeley, C. E., Wozniak, D. F., Labruyere, J., Taylor, G. T., & Olney, J. W. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4883-05.2006 · Cited by 139
Okamoto, S., Li, Z., Ju, C., Schölzke, M. N., Mathews, E. A., Cui, J., Salvesen, G. S., Bossy‐Wetzel, E., & Lipton, S. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022036399 · Cited by 138
Self-citationZeevalk, G. D., & Nicklas, W. J. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08430.x · Cited by 138
Beck, C., Wollmuth, L. P., SEEBURG, P. H., Sakmann, B. J., & Kuner, T. (1999) · Neuron · doi:10.1016/s0896-6273(00)80710-2 · Cited by 135
Banerjee, P., Samoriski, G., & Gupta, S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081976 · Cited by 134
Ditzler, K. (1991) · PubMed · Cited by 127
Rimantadine Hydrochloride and Amantadine Hydrochloride Use in Influenza A Virus Infections
Tominack, R. L., & Hayden, F. G. (1987) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30120-3 · Cited by 117
Chen, H.-S. V., & Lipton, S. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085142 · Cited by 112
Self-citationYuan, H., Erreger, K., Dravid, S. M., & Traynelis, S. F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414215200 · Cited by 107
Rogawski, M. A. (2000) · Amino Acids · doi:10.1007/s007260070042 · Cited by 103
Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells
Bresink, I., Benke, T. A., Collett, V. J., Seal, A., Parsons, C. G., Henley, J. M., & Collingridge, G. L. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15971.x · Cited by 102
Determinants of trapping block of N‐methyl‐ d ‐aspartate receptor channels
Bolshakov, K. V., Гмиро, В. Е., Tikhonov, D. B., & Magazanik, L. G. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01956.x · Cited by 98
promotes the survival of cerebellar granule cells: Pharmacological characterization
Balázs, R., Hack, N., Jørgensen, O. S., & Cotman, C. W. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90539-9 · Cited by 97
Hickenbottom, S., & Grotta, J. (1998) · Seminars in Neurology · doi:10.1055/s-2008-1040901 · Cited by 95
Sobolevsky, A. I., Koshelev, S. G., & Khodorov, B. I. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.047bf.x · Cited by 89
Maskell, P., Spéder, P., Newberry, N. R., & Bermúdez, I. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705559 · Cited by 84
β-amyloid-(1–40) increases long-term potentiation in rat hippocampus in vitro
Wu, J., Anwyl, R., & Rowan, M. J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00539-w · Cited by 80
Antonov, S. M., & Johnson, J. W. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021394 · Cited by 74
Hesselink, M. B., de Boer, B. G., Breimer, D. D., & Danysz, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018856020583 · Cited by 72
Lipton, S. A., & Chen, H.-S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401344 · Cited by 72
Self-citationMemantine in the treatment of senile dementia of the Alzheimer type
Fleischhacker, W. W., Buchgeher, A., & Schubert, H. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90047-3 · Cited by 72
Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia
Osborne, N. N. (1999) · Visual Neuroscience · doi:10.1017/s0952523899161017 · Cited by 66
Wollmuth, L. P., Kuner, T., & Sakmann, B. J. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.00033.x · Cited by 63
Molecular mechanisms of trauma-induced neuronal degeneration.
Lipton, S. A. (1993) · PubMed · Cited by 61
Self-citationTuretsky, D. M., Canzoniero, L. M. T., Sensi, S. L., Weiss, J. H., Goldberg, M. P., & Choi, D. W. (1994) · Neurobiology of Disease · doi:10.1006/nbdi.1994.0013 · Cited by 60
Modifications of neuronal phosphorylated τ immunoreactivity induced by NMDA toxicity
Couratier, P., Lesort, M. J., Sindou, P., Esclaire, F., Yardin, C., & Hugon, J. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815108 · Cited by 55
T�pper, R., Gehrmann, J., Banati, R. B., Schwarz, M., Block, F., Noth, J., & Kreutzberg, G. W. (1994) · Acta Neuropathologica · doi:10.1007/bf00294255 · Cited by 50
Zurakowski, D., Vorwerk, C. K., Gorla, M., Kanellopoulos, A. J., Chaturvedi, N., Grosskreutz, C. L., Lipton, S. A., & Dreyer, E. B. (1998) · Vision Research · doi:10.1016/s0042-6989(98)00003-0 · Cited by 49
Self-citationReiser, G., Binmöller, F.-J., & Koch, R. (1988) · Brain Research · doi:10.1016/0006-8993(88)91630-7 · Cited by 47
Neuroprotection in Acute Ischaemic Stroke
Lutsep, H. L., & Clark, W. M. (1999) · Drugs in R&D · doi:10.2165/00126839-199901010-00001 · Cited by 44
NMDA channel blockers: memantine and amino-aklylcyclohexanes - In vivo characterization
Danysz, W., Parsons, C. G., & Quack, G. (2000) · Amino Acids · doi:10.1007/s007260070045 · Cited by 41
Mealing, G. A. R., Lanthorn, T. H., Small, D. L., Murray, R. J. S., Mattes, K. C., Comas, T., & Morley, P. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29614-2 · Cited by 38
Distribution and Metabolism of the Potential Anti-Parkinson Drng Memantine in the Human
Wesemann, W., Sturm, G., & Fünfgeld, E. W. (1980) · Springer eBooks · doi:10.1007/978-3-7091-8582-7_15 · Cited by 37
Saving the Nerve from Glaucoma: Memantine to Caspaces
Naskar, R., Vorwerk, C. K., & Dreyer, E. B. (1999) · Seminars in Ophthalmology · doi:10.3109/08820539909061468 · Cited by 19
Tanila, H., Minkeviciene, R., & Banerjee, P. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92211-5 · Cited by 7
Iqbal, K., Li, L., Sengupta, A., & Grundke, I. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92213-9 · Cited by 6
Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
“, 1999), which has been proposed to be therapeutically beneficial, because normal synaptic transmission may not be influenced by the drug, but overactivation of NMDA receptors should be decreased (Chen and Lipton, 2006) (see section X.”
BackgroundInfluentialSynaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644
A Comprehensive Review of Opioid-Induced Hyperalgesia
Lee, M. O. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/145 · Cited by 1,118
The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Metadata
- Authors
- Chen, H. V., & Lipton, S. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 97
- Issue
- 6
- Pages
- 1611-1626
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2150400736
- Cited by
- 474
- References
- 104
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.